The thesis

Guardant Health is a precision oncology company with 44.3% revenue growth. Its gross margin is 65.0%, but net margin is -38.3%. The analyst consensus is BUY, despite a Decifer score of 34, indicating watchlist conviction. The high P/E ratio of -51.5x raises valuation concerns.

Why now

The recent Nasdaq gains and ISM manufacturing PMI slip in September create a risk-off environment, making Guardant Health's high valuation riskier. The USA Unemployment Rate increase to 4.2% in September may impact healthcare spending.

What to watch

Guardant Health's next quarter revenue growth rate and gross margin percentage will indicate whether its growth is sustainable. The company's ability to improve its net margin will also be crucial in determining its valuation risk.

Key risks

Guardant Health faces valuation risk due to its high P/E ratio and negative DCF intrinsic value of $-192. Execution risk is also present, as the company must maintain its 44.3% revenue growth rate to justify its valuation.

Theme exposure